1Tominaga S. A putative protein of a growth specific eDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor [J].FEBS Lett, 1989, 258:301-304.
2Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin 1-like cytokine that signals via the IL-1 receptor related protein ST2 and induces T helper type 2-associated cytokines[J].Immunity, 2005, 23: 479-490.
3Gachter T, Werenskiold AK, Klemenz R. Transcription of the interleukin-1 receptor-related T1 gene is initiated at dif ferent promoters Chem, 1996, 271 n mast cells and fibroblasts[J].J Biol 124- 129.
4Iwahana H, Hayakawa M, Kuroiwa K, et al. Molecular cloning of the chicken ST2 gene and a novel variant form of the ST2 gene product, ST2LV[J]. Biochim Biophys Acta, 2004, 1681:1-14.
5Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells[J].J Exp Med, 1998, 187:787-794.
6Dinarello CA. An IL-1 family member requires caspase i processing and signals through the ST2 receptor[J]. Immunity, 2005, 23:461- 462.
7Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin associated nuclear factor in vivo[J]. Proc Natl Acad Sci USA, 2007, 104, 282-287.
8Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker[J]. Nat Rev Drug Discov, 2008, 7: 827-840.
9Palmer G, Lipsky BP, Smithgall MD, et al. The IL-1 recep tor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33[J]. Cytokine, 2008, 42: 358-364.
10Hayakawa H, Hayakawa M, Kume A, et al. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation[J]. J BiolChem, 2007, 282: 26369-26380.
二级参考文献12
1Romagnani S.Biology of human Thl and Th2 cells[J].J Clin Immunol,1995,15:121
2Robinson DS,Hamid Q,Ying S,et al.Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma[J].N Eng J Med,1992,326: 298
3Holgate ST.The epidemic of allergy and asthma[J] .Nature,1999,402 (Suppl): B2
4Tominaga S.A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extraeellular portion of interleukin 1 receptor[J].FEBS Lett,1989,258:301
5Lohning M,Stroehmann A,Coyle JA,et al.T1/ST2 is preferentially expressed on murine Th2 cells,independent of interleukin 4,interleukin 5,and interleukin 10,and important for Th2 effector function[J].Proc Natl Acad Sci USA,1998,95:6930
6Xu D,Chan LW,Leung PB,et al.Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells[J].J Exp Med ,1998,187:787
7Prussin C,Metcalfe D.Detection of intracytoplasmic cytokine using flow cntometry and directly conjugated anti-cytokine antibodies[J].J Immunol Methods,1995,88:117
8Krouwels FH,Nocker RET,Snoek M,et al.Immunocyte to chemical and flow cytofluorimetric detection of intracellulor IL-4,IL-5 and IFN-γ:applications using blood- and airway-derived cells [J].J ImmunolMethods,1997,203: 89
9Kumar S,Tzimas N,Griswold ED,et al.Expression of ST2,an interleukin-1 receptor homologue,is induced by proinfiammatory stimuli[J].Biochem Biophys Res Commun,1997,235:474
10Levinga MK,Schrader JW.IL-4 inhibits the production of TNF-α and IL-12 by STAT6-dependent and independent mechanisms[J].J Immunol,1999,162: 5223
5Palmer G, Talabot-Ayer D, Lamacehia C, etal. Inhibition of interleukin-33 signaling attenuates the severity of experimen- tal arthritis[J]. Arthritis Rheum, 2009,60:738-749.
6Yang Z, Liang Y, Xi W, et al. Association of increased ser- um IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population[J]. Clin Exp Med, 2011,11:75-80.
7Yanaba K, Yoshizaki A, Asano Y, etal. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis [J]. Clin Rheumatol, 2011,30:825-830.
8Schmitz J, Owyang A, Oldham E, etal. IL-33, an interleu- kin-l-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines [J]. Immunity, 2005,23:479-490.
9Andhavarapu S, Roy V. Immunomodulatory drugs in multiple my- eloma [J]. Expert Rev Hematol, 2013, 6(I): 69-82.
10Jshrer K, Hofbauer SW, Zelle-Rieser C, et al. Chemokine-depen- dent B cell-T cell interact ions in chronic lymphocytic leukemia and multiple myeloma-targets for therapeutic intervention? [J]. Expert Opinion on Biological Therapy, 2012, 12: 425-441.
